EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Genetic control of sparteine and debrisoquine metabolism in man with new methods of analyzing bi modal distributions



Genetic control of sparteine and debrisoquine metabolism in man with new methods of analyzing bi modal distributions



Journal of Medical Genetics 20(5): 321-329



Debrisoquine and sparteine tests were carried out in 215 random white British subjects. There is a high degree of correlation between the urinary metabolic ratios of the 2 drugs. New mathematical techiques were developed to define phenotypes and to identify the genotypes within the dominant phenotype. The members of 15 families were tested with both debrisoquine and sparteine. Persons who are poor metabolizers of sparteine are also poor metabolizers of debrisoquine and are autosomal Mendelian recessives.

(PDF emailed within 1 workday: $29.90)

Accession: 005513419

Download citation: RISBibTeXText



Related references

The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. Journal of Medical Genetics 20(5): 321-329, 1983

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacology & Therapeutics 46(3): 377-394, 1990

The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacology & Therapeutics 46(2): 297-308, 1990

Variations in drug metabolism due to genetic polymorphism A review of the debrisoquine/sparteine type. Drug Investigation 5(1): 19-34, 1993

Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2(2): 89-92, 1992

Genetic polymorphism of sparteine debrisoquine oxidation. ISI Atlas of Science Pharmacology 2(3): 243-251, 1988

Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Therapeutic Drug Monitoring 13(2): 177-182, 1991

The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. British Journal of Clinical Pharmacology 35(4): 426-430, 1993

Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacology & Toxicology 67(4): 273-283, 1990

Metabolism of almitrine in extensive and poor metabolizers of debrisoquine sparteine. British Journal of Clinical Pharmacology 31(1): 73-76, 1991

Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes. British Journal of Clinical Pharmacology 14(4): 602P, 1982

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. British Journal of Clinical Pharmacology 15(3): 317-322, 1983

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. British Journal of Clinical Pharmacology 41(4): 311-317, 1996